During the past decade, Dana Farber Partners Cancer Care conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dana Farber Partners Cancer Care" #1 sponsor was "American College of Radiology Imaging Network" with 1 trials, followed by "Amgen" with 1 trials sponsored, "ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "CASI Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dana Farber Partners Cancer Care" #1 collaborator was "National Cancer Institute (NCI)" with 1 trials as a collaborator, "National Marrow Donor Program" with 1 trials as a collaborator and "Radiation Therapy Oncology Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Dana Farber Partners Cancer Care" are "Advanced or Metastatic Solid Tumors" (1 trials), "Cancer" (1 trials), "Carcinoma, Hepatocellular" (1 trials), "Ewing/Ewing-like Sarcoma" (1 trials) and "Fallopian Cancer" (1 trials). Many other conditions were trialed in "Dana Farber Partners Cancer Care" in a lesser frequency.

Most popular intervention types in "Dana Farber Partners Cancer Care" are "Drug" (9 trials), "Biological" (1 trials), "Genetic" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Nivolumab" (2 trials), "ARQ 501" (1 trials), "Carfilzomib" (1 trials), "Cobimetinib" (1 trials) and "DENSPM )" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dana Farber Partners Cancer Care" are 8 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Dana Farber Partners Cancer Care". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Dana Farber Partners Cancer Care, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Dana Farber Partners Cancer Care, 5 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".